| Business Summary | | Atrix
Laboratories,
Inc.
is
a
pharmaceutical
company
focused
on
advanced
drug
delivery.
With
five
patented
drug
delivery
technologies,
the
Company
is
currently
developing
a
diverse
portfolio
of
products,
including
proprietary
oncology,
pain
management
and
dermatology
products.
The
Company
also
partners
with
large
pharmaceutical
and
biotechnology
companies
to
apply
its
proprietary
technologies
to
new
chemical
entities
or
to
extend
the
patent
life
of
existing
products.
The
Company
has
strategic
alliances
with
several
pharmaceutical
companies
including
recent
collaborations
with
Sanofi-Synthelabo
Inc.,
Pfizer
Inc.,
Elan,
and
the
Novartis
company,
Geneva
Pharmaceuticals,
to
use
its
drug
delivery
technologies
and
expertise
in
the
development
of
new
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Atrix
Laboratories,
Inc.
is
a
specialty
pharmaceutical
company
with
five
patented
technologies
that
provide
drug
delivery
from
minutes
to
months.
For
the
six
months
ended
6/30/01,
revenues
rose
66%
to
$7.5
million.
Net
loss
applicable
to
Common
before
extraordinary
item
and
acctg.
change
rose
91%
to
$12.4
million.
Revenues
reflect
income
recognition
from
oncology
and
pain
management
R&D
activities.
Loss
reflects
increased
R&D
expenses
and
a
$2
million
debt
conversion
charge. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| David Bethune, 60 Chairman
and CEO | $356K | Brian Richmond, 49 CFO | -- | Richard Jackson, Ph.D., 62 Sr.
VP- R&D, Director | 272K | Charles Cox, Ph.D., 48 Sr.
VP, Corp. Devel. | 171K | Richard Dunn, 60 Sr.
VP, Drug Delivery Research | 167K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|